COSM
Cosmos Health Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.27
+2.59%Aug 24, 2026, 19:44 UTC
Cosmos Health Inc. announced the launch of its Oliv18 nutraceutical product, a whole olive polyphenol formulation, with a staged rollout beginning with direct-to-consumer e-commerce and planned expansion into retail channels.
Source:Aug 20, 2026, 00:00 UTC
Cosmos Health Inc. reported Q2 2026 GAAP revenue of $18.99 million, up 28.8% year-over-year, with a net loss of $6.09 million and adjusted EBITDA of -$1.13 million.
Jul 27, 2026, 17:05 UTC
Cosmos Health launched an AI-enabled digital subscription platform for its proprietary consumer health products across B2C and B2B channels.
Source:Jul 20, 2026, 20:00 UTC
Cosmos Health Inc. expands its distribution partnership with Pharma Cell for the Sky Premium Life brand in Albania.
Source:Jul 15, 2026, 18:15 UTC
Cosmos Health Inc. announced it repurchased an additional 100,000 shares of its common stock in the open market, bringing total repurchases to over 4.5 million shares.
Source:Jul 13, 2026, 17:00 UTC
Cosmos Health entered into a five-year partnership with Libytec to commercialize DIABIT-IS X in Greece, with Cosmos Health supplying the product and Libytec handling distribution and promotion.
Source:Jul 10, 2026, 14:55 UTC
Cosmos Health launched a subscription model for its NOOR Collagen product in the United States.
Source:Jul 1, 2026, 15:05 UTC
Cosmos Health repurchased 2.65 million shares for $500,000 in the open market and continues its buyback program.
Jun 26, 2026, 16:30 UTC
Cosmos Health signed a distribution agreement with International Medical Company (IMC) to distribute its Sky Premium Life products in Qatar, with an initial purchase order of 31,000 units.
Source:Jun 24, 2026, 19:37 UTC
Cosmos Health Inc. reported that its C-Sept PRO antiseptic solution has gained traction across leading Greek public and private hospital groups, with annualized sales poised to exceed $1.3 million.
Jun 23, 2026, 19:35 UTC
Cosmos Health signed an agreement to deploy an AI-powered call center for its subsidiary CosmoFarm S.A.
Jun 22, 2026, 14:30 UTC
Cosmos Health Inc., through its subsidiary Cana Laboratories, secured cumulative contract manufacturing orders of over 25 million units from multiple EU and international partners.
Jun 18, 2026, 19:34 UTC
CosmoFarm S.A., a subsidiary of Cosmos Health Inc., reported record Q2 2026 revenue of over $15 million, representing an annualized run-rate of over $60 million.
Source:Jun 17, 2026, 19:35 UTC
Cosmos Health entered the global skincare market by launching a new Korean-developed collagen-based skincare brand, with sales already underway in the United States.
Jun 17, 2026, 13:27 UTC
Cosmos Health, through its subsidiary Cana Laboratories, signed a five-year contract manufacturing agreement with Pharmex S.A. to produce three dermatological products totaling approximately 2.86 million units.
Jun 12, 2026, 19:33 UTC
Cosmos Health's subsidiary Cana Laboratories received contract manufacturing orders from Nassington and Verisfield for 253,657 units of medicines and pharmaceutical products.
Jun 11, 2026, 13:49 UTC
Cosmos Health received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, through December 7, 2026.
Jun 9, 2026, 19:30 UTC
Cana Laboratories secured a five-year contract manufacturing agreement with Provident Pharmaceuticals for 385,000 units of CERTORUN.
Jun 4, 2026, 19:57 UTC
Cosmos Health made its Sky Premium Life brand available for shipment across all 27 EU member states through e-commerce platform Skroutz.